Futura Medical
FUM.LFUM.L · Stock Price
Historical price data
Overview
Futura Medical has successfully transitioned from an R&D entity to a revenue-generating commercial company with the global launch of Eroxon®, its flagship OTC treatment for erectile dysfunction. Its strategy centers on developing clinically proven, topical sexual health products and commercializing them through de-risked partnerships with major consumer healthcare players like Haleon and Cooper. With a lean, semi-virtual structure and a clear pipeline, Futura aims to capitalize on the large, underserved OTC sexual health market driven by demographic trends and growing consumer self-care demand.
Technology Platform
Patented proprietary platform for developing fast-acting, topically delivered gel formulations for OTC sexual health applications, designed for rapid onset of action and local effect.
Pipeline
6| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Tadalafil 5mg (Male) + Tadalafil 5mg (Female) | Erectile Dysfunction | Phase 3 | |
| MED2005 | Erectile Dysfunction | Phase 3 | |
| Glyceryl trinitrate + MED Placebo | Erectile Dysfunction | Phase 2 | |
| Ibuprofen + Diclofenac + Methyl-salicylate / Menthol + Place... | Pain | Phase 1 | |
| MED2005 + Nitrostat 0.6Mg Sublingual Tablet + Nitro Pohl | Erectile Dysfunction | Phase 1 |
Funding History
4Opportunities
Risk Factors
Competitive Landscape
Competes with prescription PDE5 inhibitors and unproven OTC supplements. Eroxon®'s key differentiators are its FDA-authorized OTC status, rapid topical action, and clinical proof. Partnerships with major consumer health firms provide a competitive edge in marketing and distribution.